Kidney microarray data_VEGFR1 antibody treated mice
Description
The microarray data were generated using kidneys from mice receiving VEGFR1 blocking antibody or isotype control antibody treatment for two weeks
Files
Steps to reproduce
Uninephrectomized db/db mice were randomized to receive control mouse IgG1 or MF1 treatment, at 10mg/kg, sc, three times a week. 6 mice in each group. Necropsy was carried out two weeks after first dosing and mRNA was isolated from whole kidneys for microarray. Total RNA was extracted using TRIzol, followed by additional purification using Qiagen RNeasy Kit (QIAGEN, Germantown, MD). The RNA was quantified via Nanodrop UV spectrophotometry (Thermal Scientific, Wilmington, DE) and the integrity of the RNA was assessed via Agilent BioAnalyzer 2100 microfluidic electrophoresis (Agilent Technologies, Santa Clara, CA). The mRNA expression profiling studies were processed by Asuragen, Inc. (Austin, TX) using Mouse Genome 430 2.0 GeneChips according to the company’s standard operating procedures. Total RNA samples were used for preparation of biotin-labeled targets (cRNA) using a MessageAmp™ II-based protocol (Life Technologies Inc., Austin, TX). The cRNA yields were quantified by UV spectrophotometry and the distribution of transcript sizes was assessed using an Agilent Bioanalyzer 2100 microfluidic electrophoresis system. Labeled cRNA was fragmented and used for array hybridization according to the standard Affymetrix protocol. Gene expression profiles were produced using the Mouse Genome 430 2.0 ArrayAffy platform. Gene expression values were preprocessed using the MAS5 method as implemented in the BioConductor affy package for the R environment
Institutions
- Eli Lilly (United States)Indiana, Indianapolis